Cannabinol, an active ingredient in cannabis, can help protect brain cells from oxidative damage and preserve mitochondrial function.
Cannabis terpenes, the part of the plant which provides aroma and flavor, may provide therapeutic benefits in controlling pain, a new study reports.
A newly developed cannabidiol capsule can be absorbed by the body faster and penetrate the brain more quickly in mouse models of neurological disorders such as Alzheimer's disease, multiple sclerosis and TBI.
KLS-13019, a novel CBD analog, shows promise at reversing pain sensitivity and preventing symptoms of neuropathy in mouse models of chemotherapy-induced peripheral neuropathy.
CBD does not appear to reduce experimental pain intensity but does make the experience of pain less unpleasant.
Cannabidiol (CBD) increases cerebral blood flow to areas of the brain associated with memory processing, specifically the hippocampus. The findings identify a potential mechanism for the use of CBD to treat disorders associated with altered memory processing, including Alzheimer's disease, PTSD, and schizophrenia.
Cannabidiol (CBD) appears to slow the growth of glioblastoma brain cancer cells in both animal and human cell lines. CBD's anti-cancer actions target mitochondria, causing them to dysfunction and release harmful reactive oxygen species. Cancer cells treated with CBD exhibited significant decreases in mitochondrial activity.
Using purified botanical cannabidiol (CBD) to treat mouse models of Davet syndrome improved mortality and reduced behavioral symptoms associated with the condition.
Vaping cannabis products with rich THC content leads to drug-seeking behaviors in animal models.
Cannabigerol (CBG), a non-psychoactive cannabis compound, has antibiotic potential. Treating mice with MRSA, CBG worked as well as vancomycin, a powerful antibiotic, for treating the infection.
During memory tasks, people with psychosis have different patterns of activity in the prefrontal and mediotemporal brain areas compared to those without the disorder. When exposed to cannabidiol (CBD), the activity of the brain areas became more like those seen in the controls for people with psychosis. Patients reported a decrease in symptoms of psychosis following one dose of CBD. Researchers stress that no definitive conclusions could be made about the effectiveness of CBD use over a sustained period.
The effect cannabidiol has on Lennox-Gastaut syndrome may be explained by the drug-drug interaction between CBD and anti-seizure medication.
